Emerging infectious diseases (EIDs) can threaten blood safety and are a chief concern for blood operators. For novel EIDs, their transmissibility through transfusion may not be documented. This challenge may be compounded by the unavailability of diagnostic tests, in which case donor selection would be an alternative to safeguard against transmission. Therefore, to ensure blood safety, blood operators need a surveillance, modelling-based system that assesses risks. This session, presented by the Surveillance, Risk Assessment and Policy subgroup of the ISBT Working Party on Transfusion-Transmitted Infectious Diseases, will describe:
The organization of national and international cooperation on epidemiological surveillance in blood operators to identify EIDs worldwide, including mitigation strategies, risk analysis, and decision guidelines.
A process for identifying and risk assessing EIDs to guide blood-safety-related decisions: lessons from the United Kingdom.
All relevant financial relationships have been mitigated.
Discuss the epidemiological surveillance strategies to identify emerging infectious diseases that might threaten blood safety worlwide
Describe mitigation strategies based on mathematical modelling to ensure blood safety
Review the undertaking, implementation, and impact of risk assessment on donor selection criteria to ensure blood safety
Discuss lessons learned from the United Kingdom experience
Claire Reynolds, BSc, MPhil:
Nothing to Disclose
Steven Drews, PhD FCCM D(ABMM):
Johnson & Johnson (Janssen): Consultant
Abbott: Grant/Research Support (Secondary Investigators need not disclose)
Antoine Lewin, MD:
Nothing to Disclose
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
AM22-43-O: (On-Demand) Blood Safety: Epidemiological Surveillance and Risk Assessment for Emerging Pathogens (Enduring) Evaluation